COMPUGEN LTD (CGEN) Fundamental Analysis & Valuation

NASDAQ:CGEN • IL0010852080

Current stock price

2.13 USD
+0.14 (+7.04%)
At close:
2.13 USD
0 (0%)
After Hours:

This CGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. CGEN Profitability Analysis

1.1 Basic Checks

  • In the past year CGEN was profitable.
  • In the past year CGEN had a positive cash flow from operations.
  • In the past 5 years CGEN reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: CGEN reported negative operating cash flow in multiple years.
CGEN Yearly Net Income VS EBIT VS OCF VS FCFCGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 22.57%, CGEN belongs to the top of the industry, outperforming 96.71% of the companies in the same industry.
  • The Return On Equity of CGEN (34.40%) is better than 97.29% of its industry peers.
  • CGEN's Return On Invested Capital of 18.47% is amongst the best of the industry. CGEN outperforms 97.10% of its industry peers.
Industry RankSector Rank
ROA 22.57%
ROE 34.4%
ROIC 18.47%
ROA(3y)-1.75%
ROA(5y)-13.38%
ROE(3y)-6.71%
ROE(5y)-19.11%
ROIC(3y)N/A
ROIC(5y)N/A
CGEN Yearly ROA, ROE, ROICCGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • CGEN has a better Profit Margin (48.57%) than 97.87% of its industry peers.
  • The Operating Margin of CGEN (43.05%) is better than 98.65% of its industry peers.
  • CGEN has a better Gross Margin (87.29%) than 88.97% of its industry peers.
  • In the last couple of years the Gross Margin of CGEN has declined.
Industry RankSector Rank
OM 43.05%
PM (TTM) 48.57%
GM 87.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.08%
GM growth 5Y-2.09%
CGEN Yearly Profit, Operating, Gross MarginsCGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CGEN Health Analysis

2.1 Basic Checks

  • CGEN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for CGEN has been increased compared to 1 year ago.
  • Compared to 5 years ago, CGEN has more shares outstanding
  • There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGEN Yearly Shares OutstandingCGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CGEN Yearly Total Debt VS Total AssetsCGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • CGEN has an Altman-Z score of 0.13. This is a bad value and indicates that CGEN is not financially healthy and even has some risk of bankruptcy.
  • CGEN's Altman-Z score of 0.13 is fine compared to the rest of the industry. CGEN outperforms 61.12% of its industry peers.
  • There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 0.13
ROIC/WACC2.17
WACC8.53%
CGEN Yearly LT Debt VS Equity VS FCFCGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 6.56 indicates that CGEN has no problem at all paying its short term obligations.
  • The Current ratio of CGEN (6.56) is better than 64.60% of its industry peers.
  • CGEN has a Quick Ratio of 6.56. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.56, CGEN is doing good in the industry, outperforming 65.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.56
Quick Ratio 6.56
CGEN Yearly Current Assets VS Current LiabilitesCGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. CGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 331.25% over the past year.
  • The Revenue has grown by 161.14% in the past year. This is a very strong growth!
  • The Revenue has been growing by 105.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)331.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%957.14%
Revenue 1Y (TTM)161.14%
Revenue growth 3Y113.28%
Revenue growth 5Y105.2%
Sales Q2Q%4477.29%

3.2 Future

  • The Earnings Per Share is expected to decrease by -15.80% on average over the next years. This is quite bad
  • CGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 50.25% yearly.
EPS Next Y-158.99%
EPS Next 2Y-56.59%
EPS Next 3Y-45.42%
EPS Next 5Y-15.8%
Revenue Next Year186.92%
Revenue Next 2Y146.85%
Revenue Next 3Y81.75%
Revenue Next 5Y50.25%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CGEN Yearly Revenue VS EstimatesCGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20M 40M 60M 80M
CGEN Yearly EPS VS EstimatesCGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

5

4. CGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 5.76, the valuation of CGEN can be described as very cheap.
  • Based on the Price/Earnings ratio, CGEN is valued cheaply inside the industry as 98.07% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.35, CGEN is valued rather cheaply.
  • The Forward Price/Earnings Ratio is negative for CGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 5.76
Fwd PE N/A
CGEN Price Earnings VS Forward Price EarningsCGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CGEN indicates a rather cheap valuation: CGEN is cheaper than 99.03% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.43
EV/EBITDA -0.39
CGEN Per share dataCGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • The decent profitability rating of CGEN may justify a higher PE ratio.
  • CGEN's earnings are expected to decrease with -45.42% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-56.59%
EPS Next 3Y-45.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CGEN Dividend Analysis

5.1 Amount

  • CGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CGEN Fundamentals: All Metrics, Ratios and Statistics

COMPUGEN LTD

NASDAQ:CGEN (3/31/2026, 6:17:47 PM)

After market: 2.13 0 (0%)

2.13

+0.14 (+7.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-18
Inst Owners13.63%
Inst Owner Change0.72%
Ins Owners0.06%
Ins Owner Change0%
Market Cap201.39M
Revenue(TTM)72.76M
Net Income(TTM)35.34M
Analysts87.27
Price Target6.38 (199.53%)
Short Float %1.08%
Short Ratio3.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)548.64%
Min EPS beat(2)20.82%
Max EPS beat(2)1076.47%
EPS beat(4)2
Avg EPS beat(4)258.51%
Min EPS beat(4)-42.6%
Max EPS beat(4)1076.47%
EPS beat(8)3
Avg EPS beat(8)70.6%
EPS beat(12)5
Avg EPS beat(12)43.3%
EPS beat(16)8
Avg EPS beat(16)37.91%
Revenue beat(2)2
Avg Revenue beat(2)2395.59%
Min Revenue beat(2)26.15%
Max Revenue beat(2)4765.03%
Revenue beat(4)2
Avg Revenue beat(4)1170.7%
Min Revenue beat(4)-68.82%
Max Revenue beat(4)4765.03%
Revenue beat(8)3
Avg Revenue beat(8)586.15%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)8.34%
EPS NQ rev (3m)2.23%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.89%
Revenue NQ rev (1m)95.45%
Revenue NQ rev (3m)95.45%
Revenue NY rev (1m)8.3%
Revenue NY rev (3m)-13.36%
Valuation
Industry RankSector Rank
PE 5.76
Fwd PE N/A
P/S 2.77
P/FCF 6.43
P/OCF 6.37
P/B 1.96
P/tB 1.96
EV/EBITDA -0.39
EPS(TTM)0.37
EY17.37%
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)0.33
FCFY15.56%
OCF(TTM)0.33
OCFY15.71%
SpS0.77
BVpS1.09
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.01
Profitability
Industry RankSector Rank
ROA 22.57%
ROE 34.4%
ROCE 23.38%
ROIC 18.47%
ROICexc N/A
ROICexgc N/A
OM 43.05%
PM (TTM) 48.57%
GM 87.29%
FCFM 43.05%
ROA(3y)-1.75%
ROA(5y)-13.38%
ROE(3y)-6.71%
ROE(5y)-19.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.08%
GM growth 5Y-2.09%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 64.42%
Cap/Sales 0.42%
Interest Coverage 250
Cash Conversion 99.47%
Profit Quality 88.64%
Current Ratio 6.56
Quick Ratio 6.56
Altman-Z 0.13
F-Score7
WACC8.53%
ROIC/WACC2.17
Cap/Depr(3y)41.61%
Cap/Depr(5y)57.99%
Cap/Sales(3y)0.45%
Cap/Sales(5y)2.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)331.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%957.14%
EPS Next Y-158.99%
EPS Next 2Y-56.59%
EPS Next 3Y-45.42%
EPS Next 5Y-15.8%
Revenue 1Y (TTM)161.14%
Revenue growth 3Y113.28%
Revenue growth 5Y105.2%
Sales Q2Q%4477.29%
Revenue Next Year186.92%
Revenue Next 2Y146.85%
Revenue Next 3Y81.75%
Revenue Next 5Y50.25%
EBIT growth 1Y310.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.23%
OCF growth 3YN/A
OCF growth 5YN/A

COMPUGEN LTD / CGEN Fundamental Analysis FAQ

What is the fundamental rating for CGEN stock?

ChartMill assigns a fundamental rating of 6 / 10 to CGEN.


Can you provide the valuation status for COMPUGEN LTD?

ChartMill assigns a valuation rating of 5 / 10 to COMPUGEN LTD (CGEN). This can be considered as Fairly Valued.


How profitable is COMPUGEN LTD (CGEN) stock?

COMPUGEN LTD (CGEN) has a profitability rating of 6 / 10.


What is the financial health of COMPUGEN LTD (CGEN) stock?

The financial health rating of COMPUGEN LTD (CGEN) is 7 / 10.